Compare FMC Corp (FMC) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FMC Corp vs Viatris Inc — how do they compare? FMC Corp trades at $10.13 (market cap $1.30B), while Viatris Inc trades at $16.24 (market cap $18.69B). The key difference: Viatris Inc is far larger — about 14.4× FMC Corp's market cap, and FMC Corp pays the higher dividend (3.07%). Which is the better fit depends on your goals.
| FMC | VTRS | |
|---|---|---|
Market Cap | $1.30B | $18.69B |
Sector | Basic Materials | Health |
52-Week High | $40.69 | $17.86 |
52-Week Low | $10.01 | $9.49 |
Enterprise Value | $5.11B | $30.80B |
Dividend Yield | 3.07% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FMC stock trades at $10.17, down 2.82% today, amid bearish technical signals and weak fundamentals. Recent Q2 2026 earnings beat estimates but revenue missed, with full-year guidance lowered. The company faces significant profitability challenges, with a net income margin of -84.83% and negative ROE/ROA. Positive developments include a $400 million minority investment from Tessenderlo Group and ongoing debt reduction efforts.
The outlook remains cautious due to persistent earnings pressure and high debt levels, though asset sales and external funding provide liquidity support. Analyst consensus is mixed with a $11.60 price target, suggesting modest upside potential if operational improvements materialize. Key risks include volatile cash flows, competitive pressures, and macroeconomic headwinds affecting agricultural demand.
Viatris (VTRS) trades at $16.33, up 0.31% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, and revenue growth of 5% year-over-year. However, negative net income margins and a high P/E ratio of 236.2 highlight profitability challenges. Recent developments include FDA approval for Gwyn Lo contraceptive patch and ongoing divestitures to sharpen focus.
Outlook remains mixed: operational improvements and dividend payments offer stability, but persistent net losses and high debt pose risks. Analyst consensus leans Hold (61.54%), reflecting cautious optimism amid execution uncertainties. Investment appeal hinges on successful margin recovery and debt management in a competitive generic drug market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About FMC Corp
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
